✦ LIBER ✦

Gene expression profiling of the cyclin-dependent kinase inhibitor CYC202 (R-Roscovitine)

Book ID: 117659496
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 142 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)80804-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In vitro and in vivo antitumor propertie

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

✍ Steven J. McClue; David Blake; Rosemary Clarke; Angela Cowan; Lorna Cummings; Pe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 112 KB

## Abstract CDK2 inhibitors have been proposed as effective anti‐cancer therapeutics. We show here that CYC202 (__R__‐roscovitine) is a potent inhibitor of recombinant CDK2/cyclin E kinase activity (IC~50~ = 0.10 μM) with an average cytotoxic IC~50~ of 15.2 μM in a panel of 19 human tumour cell lin

Effects of the cyclin-dependent kinase i

Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes

✍ Ganka Atanasova; Ralph Jans; Nikolai Zhelev; Vanio Mitev; Yves Poumay 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 661 KB

Effects of cyclin-dependent kinase inhib

Effects of cyclin-dependent kinase inhibitor R-Roscovitine (Cyc202) on clock and cell cycle genes expression patterns. Relation with antitumor efficacy

✍ Ida Iurisci; Elisabeth Filipski; Hlynur Georgsson; Athos Gianella-Borradori; Ste 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 71 KB

423 Cyclin-dependent kinase (CDK) inhibi

423 Cyclin-dependent kinase (CDK) inhibitor CYC202 (R-roscovitine) induces clock gene mPer2 mRNA expression rhythm in tumor: relevance for antitumor efficacy

✍ E. Filipski; M. Filipski; H. Georgsson; A. Gianella-Borradori; F. Levi 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 145 KB

422 The mode of action of CYC202 (R-rosc

422 The mode of action of CYC202 (R-roscovitine) a cyclin dependent kinase inhibitor currently in phase II clinical trials

✍ S. Green; D.E. MacCallum; I.N. Fleming; J. Melville; M. Watson; S. Frame; K. Wat 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 126 KB

A phase I trial of the selective oral cy

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

✍ Benson, C; White, J; Bono, J De; O'Donnell, A; Raynaud, F; Cruickshank, C; McGra 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB